TY  - CHAP
M1  - Book, Section
TI  - Transplantation in the Treatment of Renal Failure
A1  - Azzi, Jamil
A1  - Milford, Edgar L.
A1  - Sayegh, Mohamed H.
A1  - Chandraker, Anil
A2  - Jameson, J. Larry
A2  - Fauci, Anthony S.
A2  - Kasper, Dennis L.
A2  - Hauser, Stephen L.
A2  - Longo, Dan L.
A2  - Loscalzo, Joseph
PY  - 2018
T2  - Harrison's Principles of Internal Medicine, 20e
AB  - Transplantation  of  the  human  kidney  is  the  treatment  of  choice  for  advanced  chronic  renal  failure.  Worldwide,  tens  of  thousands  of  these  procedures  have  been  performed  with  >180,000  patients  bearing  functioning  kidney  transplants  in  the  United  States  today.  When  azathioprine  and  prednisone  initially  were  used  as  immunosuppressive  drugs  in  the  1960s,  the  results  with  properly  matched  familial  donors  were  superior  to  those  with  organs  from  deceased  donors:  75–90%  compared  with  50–60%  graft  survival  rates  at  1  year.  During  the  1970s  and  1980s,  the  success  rate  at  the  1-year  mark  for  deceased-donor  transplants  rose  progressively.  Currently,  deceased-donor  grafts  have  a  92%  1-year  survival  and  living-donor  grafts  have  a  97%  1-year  survival.  Although  there  has  been  improvement  in  long-term  survival,  it  has  not  been  as  impressive  as  the  short-term  survival,  and  currently  the  “average”  (t1/2)  life  expectancy  of  a  living-donor  graft  is  around  14  years  and  that  of  a  deceased-donor  graft  is  close  to  10  years.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1169854153
ER  -